Compare Goodyear Tire & Rubber Co (GT) vs Pfizer Inc (PFE) Price & Performance

GT trades at $4.75, down 1.93% in the last 24 hours, near its 52-week low. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $1.72B in 2025, with negative profit margins and declining revenue, though cash flow from operations improved to $796M. Recent news highlights restructuring efforts and a 'shrink-to-grow' strategy to boost margins.

The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include execution of the turnaround plan, competitive pressures, and macroeconomic headwinds. Institutional sentiment is mixed, with 34.6% of analysts rating it a buy.

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.